Drug Profile
Adimlecleucel - Atara Biotherapeutics
Alternative Names: ATA 230; CMV targeted T-cell therapy - Atara/MSKCC; CMV-CTL - Atara/MSKCC; CMV-peptide-specific T-cells - Atara/MSKCC; CMV-pp65 CTL - Atara/MSKCC; CMVpp65-specific T-cells - Atara/MSKCC; Cytomegalovirus virus specific cytotoxic T-lymphocytes - Atara/MSKCC; Cytomegalovirus-pp65-specific-cytotoxic-T-lymphocytes-Atara/MSKCC; Cytomegalovirus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer CenterLatest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Class Gene therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cytomegalovirus infections
Most Recent Events
- 08 Oct 2021 Phase-II development is still ongoing for Cytomegalovirus infections treatment in USA (NCT02136797)
- 04 Apr 2019 Atara Biotherapeutics completes an expanded access protocol for Cytomegalovirus infections treatment (NCT03010332)
- 11 Dec 2017 Updated adverse events and efficacy data from a phase II trial in Cytomegalovirus infections treatment released by Atara Biotherapeutics